PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21792892-3	2012	We hypothesized that WP1066, a novel inhibitor of STAT3 signaling, would enhance the antitumor activity of cyclophosphamide (CTX) against melanoma, including disease within the CNS.	Cyclophosphamide	107-123	V-set and immunoglobulin domain containing 2	Mus musculus	125-128	
22803439-1	2012	OBJECTIVE: To explore the mechanism of polypeptide extract from scorpion venom (PESV) on promoting anti-tumor effects of cyclophosphamide (CTX).	Cyclophosphamide	121-137	V-set and immunoglobulin domain containing 2	Mus musculus	139-142	
19761687-2	2009	SMMC-7721 cells were inoculated into mice treated with 0, 2, 5 or 10 mg/kg cyclophosphamide (CTX).	Cyclophosphamide	75-91	V-set and immunoglobulin domain containing 2	Mus musculus	93-96	
21076492-2	2010	The objective of this study was to investigate its protective activity against cyclophosphamide (CTX)-induced toxicity in mouse models.	Cyclophosphamide	79-95	V-set and immunoglobulin domain containing 2	Mus musculus	97-100	
22946026-7	2012	A decreased cyclophosphamide dose in combination with two doses of vasostatin (V2 + CTX scheme) inhibits tumor growth similarly to a larger dose of cyclophosphamide alone.	Cyclophosphamide	12-28	V-set and immunoglobulin domain containing 2	Mus musculus	84-87	
21381781-1	2011	The aim of this study was to investigate the enhancement of Ganoderma atrum polysaccharide (PSG-1) on cyclophosphamide (CTX)-induced antitumor effect in sarcoma 180 (S-180)-bearing mice.	Cyclophosphamide	102-118	V-set and immunoglobulin domain containing 2	Mus musculus	120-123	
20568461-1	2010	OBJECTIVE: To compare the methods for developing immune-suppressed mice models induced by cyclophosphamide (CTX) with different dosages and ways.	Cyclophosphamide	90-106	V-set and immunoglobulin domain containing 2	Mus musculus	108-111	
19464751-1	2010	As alkylating agents, cyclophosphamides (CTX) are used to treat various cancers and, ironically, to boost immune responses.	Cyclophosphamide	22-39	V-set and immunoglobulin domain containing 2	Mus musculus	41-44	
16453328-1	2006	BACKGROUND: Cyclophosphamide (CTX) and ifosfamide (IFX) are alkylating agents used to treat osteosarcoma (OS).	Cyclophosphamide	12-28	V-set and immunoglobulin domain containing 2	Mus musculus	30-33	
19168513-1	2009	AIMS: Heart failure is a life-threatening complication of high-dose cyclophosphamide (CTX) chemotherapy, and the present study aimed at identifying the mechanism involved in mice.	Cyclophosphamide	68-84	V-set and immunoglobulin domain containing 2	Mus musculus	86-89	
17156807-1	2007	Cyclophosphamide (CTX) is in the nitrogen mustard group of alkylating antineoplastic chemotherapeutic agents.	Cyclophosphamide	0-16	V-set and immunoglobulin domain containing 2	Mus musculus	18-21	
19619437-1	2009	BACKGROUND AND OBJECTIVE: Cyclophosphamide (CTX) is a commonly used clinical antitumor drug with severe side effects.	Cyclophosphamide	26-42	V-set and immunoglobulin domain containing 2	Mus musculus	44-47	
18619249-3	2008	METHODS: The immunity-deficiency model was induced by intraperitoneal injection of cyclophosphamide (CTX) at the dose of 100 mg/kg in mice; all the animals were divided into normal control group, immunity-deficiency model group, Part III treated group (300 mg/kg) and positive control group (TSPG, 300 mg/kg).	Cyclophosphamide	83-99	V-set and immunoglobulin domain containing 2	Mus musculus	101-104	
18196608-6	2008	Tumor-bearing mice treated with BBSKE showed an increase of life span with a comparable effect to cyclophosphamide (CTX).	Cyclophosphamide	98-114	V-set and immunoglobulin domain containing 2	Mus musculus	116-119	
17440723-1	2007	Single administration of low dose cyclophosphamide (CTX) was previously reported to enhance the antitumor efficacy of immunotherapies.	Cyclophosphamide	34-50	V-set and immunoglobulin domain containing 2	Mus musculus	52-55	
17548941-1	2007	We examined whether low dose radiation (LDR) exposure (75 mGy) could increase the therapeutic efficacy of cyclophosphamide (CTX) by comparing the effects of tumor suppression, tumor cell apoptosis, cell cycle and proliferation of bone marrow in vivo.	Cyclophosphamide	106-122	V-set and immunoglobulin domain containing 2	Mus musculus	124-127	
17918443-2	2007	METHODS: The immunity-deficiency model was induced by intraperitoneal injection (ip) of cyclophosphamide (CTX) at the dose of 100 mg/ kg in mice which were randomly divided into normal control group, immunity-deficiency model group, SKC treated group (250 mg/kg, 500 mg/kg) and positive control group (500 mg/kg).	Cyclophosphamide	88-104	V-set and immunoglobulin domain containing 2	Mus musculus	106-109	
17198082-1	2007	Although cyclophosphamide (CTX) has been clearly shown to enhance active specific and adoptive immunotherapies, the mechanism(s) underlying these beneficial effects have not been clearly defined.	Cyclophosphamide	9-25	V-set and immunoglobulin domain containing 2	Mus musculus	27-30	
17250437-2	2006	Immunological and biochemical studies were here carried out to investigate protective effects of ethanolic extract of Andrographis paniculata against cyclophosphamide (CTX) induced toxicity in vivo.	Cyclophosphamide	150-166	V-set and immunoglobulin domain containing 2	Mus musculus	168-171	
16155834-4	2005	The tumor growth was markedly inhibited by cyclophosphamide (CTX) in model of S( 180) with IR of 70.7% and in model of HT-29 with IR of 67.1%, compared with control groups, both P< 0.01; apoptosis induced by CTX was markedly observed by in microscope examination.	Cyclophosphamide	43-59	V-set and immunoglobulin domain containing 2	Mus musculus	61-64	
14679003-4	2003	We therefore investigated whether such metronomic therapy with the alkylating agent cyclophosphamide (CTX) could be effectively combined with immunotherapy eliciting tumor-reactive CTLs.	Cyclophosphamide	84-100	V-set and immunoglobulin domain containing 2	Mus musculus	102-105	
10884587-13	2000	In the MC38 tumor model, combination treatment of established tumors with BCH-1393 and Cy (CTX) at 50 mg/kg resulted in a significant delay in tumor growth compared to CTX treatment alone.	Cyclophosphamide	87-89	V-set and immunoglobulin domain containing 2	Mus musculus	91-94	
12019144-5	2002	We tested one such drug, cyclophosphamide (CTX), in a protocol wherein the drug was administered to mice at low doses, of approximately 10-40 mg/kg on a daily basis through the drinking water.	Cyclophosphamide	25-41	V-set and immunoglobulin domain containing 2	Mus musculus	43-46	
12578576-1	2001	The life span of NS-1 myeloma-bearing mice was observed after treating with KRN7000 and combined with cyclophosphamide (CTX).	Cyclophosphamide	102-118	V-set and immunoglobulin domain containing 2	Mus musculus	120-123	
12907602-2	2003	Here we show that the administration of cyclophosphamide (CTX) at the maximum tolerable dose with 21-day breaks or at more frequent low-dose (metronomic) schedules have opposite effects on the mobilization and viability of circulating endothelial progenitors (CEPs) in immunodeficient mice bearing human lymphoma cells.	Cyclophosphamide	40-56	V-set and immunoglobulin domain containing 2	Mus musculus	58-61	
10884587-13	2000	In the MC38 tumor model, combination treatment of established tumors with BCH-1393 and Cy (CTX) at 50 mg/kg resulted in a significant delay in tumor growth compared to CTX treatment alone.	Cyclophosphamide	87-89	V-set and immunoglobulin domain containing 2	Mus musculus	168-171	
34945585-1	2021	We previously reported that the immunostimulatory activity of heat-killed Latilactobacillus sakei K040706 in macrophages and cyclophosphamide (CTX)-treated mice.	Cyclophosphamide	125-141	V-set and immunoglobulin domain containing 2	Mus musculus	143-146	
10218130-2	1999	with cyclophosphamide (CTX) pretreatment.	Cyclophosphamide	5-21	V-set and immunoglobulin domain containing 2	Mus musculus	23-26	
9197327-2	1997	Single doses of cyclophosphamide (CTX) from 80 to 200 mg/kg were administered to C57B16/J mice.	Cyclophosphamide	16-32	V-set and immunoglobulin domain containing 2	Mus musculus	34-37	
33778186-2	2021	Cyclophosphamide (CTX) not only directly kills tumors but also causes immunogenic cell death, providing a promising source of antigens for cancer vaccines.	Cyclophosphamide	0-16	V-set and immunoglobulin domain containing 2	Mus musculus	18-21	
9673408-2	1998	Similarly, IL-1 is reported to accelerate recovery following myelosuppressive treatment with doxorubicin (AdR), cis-platinum (DDP) and cyclophosphamide (CTx).	Cyclophosphamide	135-151	V-set and immunoglobulin domain containing 2	Mus musculus	153-156	
1585385-4	1992	In contrast, the activation of cyclophosphamide (cytoxan, CTX), which was used in these studies as a comparative control, was not affected by the absence of the hormone supplement.	Cyclophosphamide	31-47	V-set and immunoglobulin domain containing 2	Mus musculus	58-61	
1924852-1	1991	The interaction between fractionated heat treatment and fractionated drug treatment with cyclophosphamide (CTX) was investigated in a transplantable C3H mouse mammary carcinoma inoculated into the hind leg of C3D2F1/Bom mice.	Cyclophosphamide	89-105	V-set and immunoglobulin domain containing 2	Mus musculus	107-110	
1830248-1	1991	In an effort to improve the therapeutic efficacy and selectivity of cyclophosphamide (CTX), cis-diamminedichloroplatinum(II) (CDDP), and carboplatin (Carbo), these antitumor alkylating agents were combined with the 2-nitroimidazole drug etanidazole (ETA).	Cyclophosphamide	68-84	V-set and immunoglobulin domain containing 2	Mus musculus	86-89	
34062413-3	2021	The aim of this study was to investigate the synergistic anti-tumor activity of SBD with cyclophosphamide (CTX) and the possibly underlying mechanisms in treating the hepatoma 22 (H22) -bearing mice.	Cyclophosphamide	89-105	V-set and immunoglobulin domain containing 2	Mus musculus	107-110	
3145205-6	1988	For cyclophosphamide (CTX) and mitomycin C (MMC) both DER and TER (thermal enhancement ratio) were significantly larger than 1.0.	Cyclophosphamide	4-20	V-set and immunoglobulin domain containing 2	Mus musculus	22-25	
35268821-3	2022	Cyclophosphamide (CTX) is a commonly used chemotherapeutic drug that suppresses the host immune system, intestinal mucosa inflammation, and dysbiosis of the intestinal flora.	Cyclophosphamide	0-16	V-set and immunoglobulin domain containing 2	Mus musculus	18-21	
2504842-1	1989	The ability of cyclophosphamide (CTX) and mitomycin C (MMC) to modify the expression of thermotolerance in vivo at 43.5 degrees C was investigated in a transplantable C3H mouse mammary carcinoma grown s.c. in feet of C3D2F1/Bom mice.	Cyclophosphamide	15-31	V-set and immunoglobulin domain containing 2	Mus musculus	33-36	
3709709-3	1986	Studies are described that demonstrate the ability of lithium (Li) to enhance the recovery of the total peripheral blood neutrophil and pluripotential stem cell (CFU-S and CFU-Mix) populations per femur from mice administered cyclophosphamide (CTX)(200 mg/kg body weight).	Cyclophosphamide	226-242	V-set and immunoglobulin domain containing 2	Mus musculus	244-247	
3948164-1	1986	A series of experiments in DBA/2J mice evaluated the biological and pharmacokinetic interactions of the alkylating agent cyclophosphamide (CTX) and the histamine-H2 antagonists cimetidine (CMT) and ranitidine (RNT).	Cyclophosphamide	121-137	V-set and immunoglobulin domain containing 2	Mus musculus	139-142	
2932218-5	1985	They were resistant to treatment of mice with high-dose cyclophosphamide (CTX).	Cyclophosphamide	56-72	V-set and immunoglobulin domain containing 2	Mus musculus	74-77	
6357429-1	1983	Resistance of mouse M5076 (M5) ovarian reticular cell sarcoma to cyclophosphamide (CTX) was obtained in vivo by repeated drug treatment followed by transplantation of the regrowing tumor.	Cyclophosphamide	65-81	V-set and immunoglobulin domain containing 2	Mus musculus	83-86	
32504759-1	2020	AIMS: Cyclophosphamide (CTX) is an effective anti-tumor and immunosuppressive agent, but it induces nephrotoxicity in clinical applications.	Cyclophosphamide	6-22	V-set and immunoglobulin domain containing 2	Mus musculus	24-27	
7034931-1	1982	Using the MOPC 104E murine plasmacytoma model, Ghanta et al have shown major synergism when cisplatin was added to a treatment program with BCNU and cyclophosphamide (CTX).	Cyclophosphamide	149-165	V-set and immunoglobulin domain containing 2	Mus musculus	167-170	
32982414-6	2020	Furthermore, 72 Balb/c nude mice with breast cancer were randomly assigned to three groups that received different doses of cyclophosphamide (CTX) (control, 100 mg/kg, and 200 mg/kg), and the alterations in serum AMH levels and ovarian follicles were recorded and analyzed.	Cyclophosphamide	124-140	V-set and immunoglobulin domain containing 2	Mus musculus	142-145	
6776030-3	1980	Pretreatment with 100 mg/kg of cyclophosphamide (CTX) 3 d before antigen failed to alter this pattern, but treatment 3 d after antigen administration abrogated both DTH and DCMC.	Cyclophosphamide	31-47	V-set and immunoglobulin domain containing 2	Mus musculus	49-52	
922753-4	1977	When given together with noncurative doses of cyclophosphamide (CTX), ALK-NABS acts synergistically.	Cyclophosphamide	46-62	V-set and immunoglobulin domain containing 2	Mus musculus	64-67	
33989716-1	2021	The aim of the present study is to assess whether low level laser therapy (LLLT) can protect ovaries from chemotherapy-induced gonadotoxicity using a mice model of premature ovarian failure induced by cyclophosphamide (CTX).	Cyclophosphamide	201-217	V-set and immunoglobulin domain containing 2	Mus musculus	219-222	
33044099-1	2020	OBJECTIVE: To establish a mouse model of bioluminescent Klebsiella pneumoniae-induced lung infection, under different infection states after pretreatment with various dosages of cyclophosphamide (CTX).	Cyclophosphamide	178-194	V-set and immunoglobulin domain containing 2	Mus musculus	196-199	
31734373-6	2020	In this study, a purified polysaccharide was primarily extracted from the flowers of Apios americana Medik (AAM), which can improve the immunosuppression induced by cyclophosphamide (CTX).	Cyclophosphamide	165-181	V-set and immunoglobulin domain containing 2	Mus musculus	183-186	
32171146-3	2020	Through the analysis of body weight, spleen and thymus indexes, peripheral blood routine and pathological section of femur, it was obviously that DBD could significantly improve acetylphenylhydrazine (APH) + cyclophosphamide (CTX) induced anemia mice in the present work.	Cyclophosphamide	208-224	V-set and immunoglobulin domain containing 2	Mus musculus	226-229	
31889842-1	2020	In order to research the role of soybean oligosaccharides (SBOSs) on improvements in the microenvironment of intestinal flora and immune function of cyclophosphamide (CTX) immunosuppressive mice.	Cyclophosphamide	149-165	V-set and immunoglobulin domain containing 2	Mus musculus	167-170	
31089650-2	2019	In this study, the aim was to investigate the effect of polysaccharides from Cordyceps gunnii mycelia (PPS) in cyclophosphamide (CTX)-induced immunodeficient mice.	Cyclophosphamide	111-127	V-set and immunoglobulin domain containing 2	Mus musculus	129-132	
30862756-1	2019	Cyclophosphamide (CTX) is widely used in cancer chemotherapy, but it often induces mucositis, in which the disruption of the gut microbiota might play a pivotal role.	Cyclophosphamide	0-16	V-set and immunoglobulin domain containing 2	Mus musculus	18-21	
31031723-1	2019	Cyclophosphamide (CTX), a clinically important antineoplastic drug, also leads to some side effects such as nausea, vomiting and diarrhea in the consumer.	Cyclophosphamide	0-16	V-set and immunoglobulin domain containing 2	Mus musculus	18-21	
30887825-1	2019	AIM: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.	Cyclophosphamide	40-56	V-set and immunoglobulin domain containing 2	Mus musculus	58-62	
30524884-2	2018	Recently, the combination of autologous tumor lysate-pulsed dendritic cells (DC) and metronomic cyclophosphamide (mCTX) was reported as a feasible and well-tolerated treatment in malignant pleural mesothelioma patients and further as a method to reduce circulating Tregs.	Cyclophosphamide	96-112	V-set and immunoglobulin domain containing 2	Mus musculus	114-118	
30629411-3	2019	In this study, we first investigated the effects of CK on myelosuppression in mice induced by cyclophosphamide (CTX).	Cyclophosphamide	94-110	V-set and immunoglobulin domain containing 2	Mus musculus	112-115	
28140733-5	2017	BD model mice were established by injecting N-acetylphenylhydrazine (APH) and cyclophosphamide (CTX) (ip).	Cyclophosphamide	78-94	V-set and immunoglobulin domain containing 2	Mus musculus	96-99	
28826042-1	2018	Oxidative DNA damage in bone marrow cells is the main side effect of chemotherapy drugs including cyclophosphamide (CTX).	Cyclophosphamide	98-114	V-set and immunoglobulin domain containing 2	Mus musculus	116-119	
30026678-8	2018	Conclusions: This study suggested that orally administered L.plantarum KLDS1.0318 may effectively accelerate the recovery of immunosuppressive mice caused by cyclophosphamide (CTX).	Cyclophosphamide	158-174	V-set and immunoglobulin domain containing 2	Mus musculus	176-179	
29078731-3	2018	In the present study, the immune regulatory effect of LP was investigated in normal mice and Lewis lung carcinoma (LLC)-bearing mice treated with cyclophosphamide (CTX).	Cyclophosphamide	146-162	V-set and immunoglobulin domain containing 2	Mus musculus	164-167	
29156526-1	2018	BACKGROUND: Cyclophosphamide (CTX) is a widely used antitumor drug that can suppress the immune system.	Cyclophosphamide	12-28	V-set and immunoglobulin domain containing 2	Mus musculus	30-33	
26116901-1	2015	Cancer chemotherapy regimens, particularly those employing high-dose cytotoxic drugs such as cyclophosphamide (CTX), have been considered to be immune suppressive.	Cyclophosphamide	93-109	V-set and immunoglobulin domain containing 2	Mus musculus	111-114	
27061017-5	2016	After C57BL/6 mice were treated with intermediate- and high-dose (25/50 mg/kg) cyclophosphamide (CTX) for 10 days, the body-weight, changes in thymus and spleen, number of white blood cells (WBCs), red blood cells (RBCs), and platelets (PLTs) and changes in bone marrow in the mice were systematically evaluated at the next 2, 7 and 14 days.	Cyclophosphamide	79-95	V-set and immunoglobulin domain containing 2	Mus musculus	97-100	
26822718-2	2016	It is well-known that cyclophosphamide (CTX) applied at high dose often damages the immune system by inhibiting immune cell proliferation.	Cyclophosphamide	22-38	V-set and immunoglobulin domain containing 2	Mus musculus	40-43	
26669198-1	2015	OBJECTIVE: To observe the effect of acupuncture and moxibustion intervention on the contents of serum IL-7 and IL-18 and white blood cell counts in cyclophosphamide (CTX)-induced hypofunction of immunity in tumor-bearing mice, so as to explore its mechanism underlying improvement of immune suppression caused by chemotherapy.	Cyclophosphamide	148-164	V-set and immunoglobulin domain containing 2	Mus musculus	166-169	
28499912-1	2017	Cyclophosphamide (CTX) is a chemotherapeutic agent widely used to treat ovarian, breast, and hematological cancers as well as autoimmune disorders.	Cyclophosphamide	0-16	V-set and immunoglobulin domain containing 2	Mus musculus	18-21	
30133214-1	2016	Objective: To investigate the protective effect and mechanism of Wuzi Yanzong prescription on apoptosis in germ cell of adult male mice induced by cyclophosphamide( CTX).	Cyclophosphamide	147-163	V-set and immunoglobulin domain containing 2	Mus musculus	165-168	
25797116-3	2015	MATERIALS AND METHODS: The blood deficiency mice model was induced by being hypodermically injected with N-acetyl phenylhydrazine (APH) and being intraperitoneally injected with cyclophosphamide (CTX).	Cyclophosphamide	178-194	V-set and immunoglobulin domain containing 2	Mus musculus	196-199	
25895394-1	2014	OBJECTIVE: To study the protective effect of polysaccharides from corn silk (PCS) against cyclophosphamide (CTX) induced host damages in mice bearing H22 tumors.	Cyclophosphamide	90-106	V-set and immunoglobulin domain containing 2	Mus musculus	108-111	
25152523-1	2014	The adverse effects of the anti-cancer agent cyclophosphamide (CTX) on follicular growth and ovarian angiogenesis were investigated in mice.	Cyclophosphamide	45-61	V-set and immunoglobulin domain containing 2	Mus musculus	63-66	
23791611-2	2013	We aimed to investigate the alterations of mucosal barrier and colonization resistance in mouse treated with cyclophosphamide (CTX) to further understand the translocation mechanism.	Cyclophosphamide	109-125	V-set and immunoglobulin domain containing 2	Mus musculus	127-130	
24709186-8	2014	The chemotherapy-induced bone marrow suppression was established by intraperitoneally injecting cyclophosphamide (CTX) into the mice which performed as the chemotherapy group.	Cyclophosphamide	96-112	V-set and immunoglobulin domain containing 2	Mus musculus	114-117	
25555880-1	2014	OBJECTIVE: Cyclophosphamide (CTX) can attack tumour cells, but can also damage the other cells and microstructures of an organism at different levels, such as haematopoietic cells, liver cells, peripheral lymphocyte DNA, and genetic materials.	Cyclophosphamide	11-27	V-set and immunoglobulin domain containing 2	Mus musculus	29-32	
24949077-3	2014	The present paper emphasizes antitumor effect of FZFA combined with cyclophosphamide (CTX) on C57BL/6 mice subcutaneously injected with Lewis lung cancer cells, Comparing it with that of CTX.	Cyclophosphamide	68-84	V-set and immunoglobulin domain containing 2	Mus musculus	86-89	
24067072-2	2013	Pre-pubertal female C57BL/6J mice (n = 78) were assigned to receive placebo (controls), 200 mg/kg (group A), or 120 mg/kg (group B) of cyclophosphamide (CTX) on postnatal day 18.	Cyclophosphamide	135-151	V-set and immunoglobulin domain containing 2	Mus musculus	153-156	
23838374-4	2013	METHODS: Female mice were injected intraperitoneally with 50 mg/kg cyclophosphamide (CTX).	Cyclophosphamide	67-83	V-set and immunoglobulin domain containing 2	Mus musculus	85-88	
23847953-1	2013	OBJECTIVE: To explore the inhibitory effect of combined administration of bear bile powder (BBP) and cyclophosphamide (Cytoxan, CTX) on colorectal cancer liver metastasis by regulating tumor promotion inflammation microenvironment.	Cyclophosphamide	101-117	V-set and immunoglobulin domain containing 2	Mus musculus	128-131	
23407364-1	2013	20(S)-protopanaxadiol (PPD) is an extract of Panax quinquefolius L. The aim of this study was to investigate the effect of PPD on the antitumor activity and toxicity of cyclophosphamide (CTX) in tumor-bearing mice.	Cyclophosphamide	169-185	V-set and immunoglobulin domain containing 2	Mus musculus	187-190	
23231045-2	2013	Cyclophosphamide (CTX) can induce oxidative stress in bone marrow resulting in suppression of anti-oxdiantive enzymes and causes myelosuppression.	Cyclophosphamide	0-16	V-set and immunoglobulin domain containing 2	Mus musculus	18-21